Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.
Can Fam Physician
; 63(11): 844-852, 2017 Nov.
Article
en En
| MEDLINE
| ID: mdl-29138154
ABSTRACT
OBJECTIVE:
To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain. QUALITY OF EVIDENCE A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement. MAIN MESSAGE Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.CONCLUSION:
Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Dolor Crónico
/
Analgésicos
/
Neuralgia
Tipo de estudio:
Guideline
/
Systematic_reviews
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Can Fam Physician
Año:
2017
Tipo del documento:
Article